The study demonstrated a favorable safety profile, with the consolidated single-infusion regimen showing fewer infusion reactions compared to the reference regimen.

Phase 3 data support a lower age threshold for linaclotide, making it the first prescription therapy approved for functional constipation in patients ages 2 to 5.

The Agency will review supplemental data from AstraZeneca to address ODAC concerns regarding overall survival benefit, trial design interpretation, and cardiovascular safety.

Investigational oral substrate therapy BBP-418 demonstrated significant increases in alpha-dystroglycan glycosylation and improved ambulatory function in the phase 3 FORTIFY interim analysis.

The Trump administration has issued a directive shutting key US health research officials out of global discussions on virus outbreaks, according to CNN. Specifically, officials from the National ...

An ongoing phase 2 trial is assessing the efficacy of elunetirom for adults with bipolar depression taking a mood stabilizer.

The NIAID evaluates treatment and prevention options for a wide range of diseases and conditions, which includes what research gets funded and which vaccines are developed. HealthDay News — Dr Jeffery ...

A second opinion physician was held liable for an unnecessary hysterectomy despite a laboratory mix-up at the original facility.

For preschool-aged children presenting to the emergency department with moderate-to-severe acute wheezing, azithromycin does not lead to a reduction in the seve ...

Retatrutide demonstrated substantial dose-dependent improvements in waist circumference and crucial cardiovascular risk factors, including non-HDL-C, triglycerides, systolic blood pressure, and ...

A phase 3 study assessed pozdeutinurad compared with placebo in patients with gout who were inadequate responders to prior therapies.